Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
39 hedge funds and large institutions have $23.6M invested in Paratek Pharmaceuticals, Inc. in 2013 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 9 closing their positions.
800% more call options, than puts
Call options by funds: $27K | Put options by funds: $3K
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
8% more capital invested
Capital invested by funds: $21.8M → $23.6M (+$1.74M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 42 → 39 (-3)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$625K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$382K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$331K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$155K |
| 5 |
SG Americas Securities
New York
|
+$106K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LOM
Loeb Offshore Management
New York
|
-$321K |
| 2 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
-$313K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$161K |
| 4 |
Morgan Stanley
New York
|
-$160K |
| 5 |
Renaissance Technologies
New York
|
-$117K |
PRTK Hedge Fund Activity: Q4 2013 in Review
39 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q4 2013, worth a combined $23.6M — up 8% from $21.8M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of PRTK and 6 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 12 added.
The largest buyer was AQR Capital Management, adding an estimated $625K. The largest seller was Loeb Offshore Management, exiting entirely with an estimated $321K sold.
- 39 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q4 2013, down from 42 in Q3 2013.
- Funds reported $23.6M of Paratek Pharmaceuticals, Inc. stock for Q4 2013, up 8% quarter-over-quarter.
- 6 funds opened new Paratek Pharmaceuticals, Inc. positions in Q4 2013 and 9 closed out, a net change of -3 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q4 2013 was AQR Capital Management, an estimated $625K added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q4 2013 was Loeb Offshore Management, an estimated $321K sold.
Based on aggregated 13F filings for Q4 2013.